Skip to main content
Skip to footer

Smart New Normal in Medication Management-Personalized, Integrated, and Flexible 

Smart New Normal in Medication Management

Dr. Hilde Vanaken

Head of Industry Leaders, Life Sciences and Healthcare, TCS

You have these already downloaded

We have sent you a copy of the report to your email again.

Medication adherence continues to remain one of the biggest healthcare challenges not only for commercially available treatments but also for Investigational Medicinal Products (IMPs) in clinical trials. Research has shown that, across all therapeutic areas, adherence rates drop by 40% within a year of clinical trial commencement. Incorrect medication intake can pose multiple risks such as sub-optimal therapeutic effects, higher chance of side effects, increased use of medical resources, or even incorrect assessments and conclusions for the Investigational Medicinal Products with an early termination of potential life-saving compounds. Physicians too have limited to no real-time insights into the activities at home, and hence incorrect intake is picked up only during the next interaction or a few even go unnoticed. This can have a significant impact on the safety and health of patients.

Read on to find what the next generation medication management in clinical trials should entail

Read More

About the authors

Dr. Hilde Vanaken
Dr Hilde is a passionate generalist with a track record of turning large & complex concepts into realization through collaboration. She joined TCS in 2019 as a Senior Industry Advisor for TCS Life Sciences & Healthcare having spent the previous +25 years at the pharma side where she shaped & led multiple cross-departmental & cross-pharma preclinical & clinical programs to success stories, e.g. Janssen’s Integrated Smart Trial & Engagement program, Transcelerate eConsent program.
Read more about authorRead more about author Read more about author

Related reading

Next-gen clinical trials on a digital platform

Customer Testimonial | 27 Jan 2023

Adopting a Design Thinking Approach for Risk-Based Monitoring

White Paper | 23 Dec 2022

The new age digital contract research organizations

White Paper | 23 Dec 2022

Bayer overhauls its trial planning process

White Paper | 23 Dec 2022

Transformation starts here

Learn how we can help you bring drugs to the market faster.

Talk to our experts

Find out more